Nanobiotix/$NBTX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Nanobiotix

Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.

Ticker

$NBTX
Primary listing

Industry

Biotechnology
Headquarters

Employees

108

Nanobiotix Metrics

BasicAdvanced
$335M
-
-$1.65
1.55
-

What the Analysts think about Nanobiotix

Analyst ratings (Buy, Hold, Sell) for Nanobiotix stock.

Bulls say / Bears say

Regulatory harmonization in Europe reclassifying JNJ-1900 (NBTXR3) as a medicinal product and filing a new composition-of-matter patent strengthens global IP protection and may accelerate market approval and reimbursement.
Phase 1 pancreatic cancer study results showed median overall survival of 23 months versus historical 19.2 months with a favorable safety profile, supporting further development in this high-need indication.
Johnson & Johnson’s dosing of the first patient in the randomized Phase 2 CONVERGE NSCLC trial expands the clinical pipeline and validates external commitment to NBTXR3’s lung cancer programs.
Nanobiotix reported a net loss of €68.1 million for FY 2024 and held €49.7 million in cash at year-end, with Q1 2025 cash down to €39.8 million, suggesting potential dilution or financing risk as runway approaches mid-2026.
Amendment to the global licensing agreement with Johnson & Johnson reduced overall deal value by $105 million, lowering potential future milestone payments and capping upside from lead programs.
The pivotal Phase 3 NANORAY-312 trial for head and neck cancer remains pending interim analysis after global sponsorship transfer by Q3 2025, posing timeline and clinical execution risks.
Data summarised monthly by Lightyear AI. Last updated on 23 Jul 2025.

Nanobiotix Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Nanobiotix Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $NBTX

Sign up or log in to buy
Capital at risk
Market openADR

Upcoming events

No upcoming events
FAQs